Treatment of Childhood Onset Psychiatric Disorders With Intravenous Immunoglobulin (IVIg)
Status:
Completed
Trial end date:
2000-06-01
Target enrollment:
Participant gender:
Summary
Recent research studies of early onset-obsessive compulsive disorder (OCD) and Tourette's
syndrome have questioned whether autoimmunity could play a role in the development of these
conditions. As a result, there has been an increased interest in the field of research on the
potential involvement of autoimmunity in other psychiatric conditions like schizophrenia.
Autoimmune conditions occur when the normal immune system of the body begins working against
itself. The immune system recognizes cells as foreign and begins to attack them.
There are several similarities between autoimmune diseases and schizophrenia. Genetics play
some role in the development of both diseases. Both conditions show a similar course, and
both conditions tend to show worsening of symptoms when exposed to stress.
Previous research studies have shown intravenous immunoglobulin to be safe and effective when
used in neurologic diseases involving the immune system. Presently the NIMH is testing the
effectiveness of IVIg in OCD and Tourette's syndrome.
Intravenous Immunoglobulin IVIg is a medication that has been used to treat diseases like
Kawasaki disease, systemic juvenile rheumatoid arthritis, lupus nephritis, and idiopathic
thrombocytopenic purpura. The drug modifies the body's natural immune reactions.
This research study is a 13-week trial of intravenous immunoglobulin (IVIg) on patients
suffering from childhood-onset schizophrenia, who have failed to respond to other therapies.